Liraglutide biosimilar (Zhongmei Huadong) | Interleukin Related interleukin-related.com

Product Name :
Liraglutide biosimilar (Zhongmei Huadong)

Search keywords :
GLP-1R

drugId :
null

Target Vo:
Glucagon-like peptide 1 receptor

Target Vo Short Name :
GLP1R

Moa_Name:
Glucagon-like peptide 1 receptor agonists

First Approval Country :
Mainland China

First Approval Date Filter:
2023

Origin Company_Name :
Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd

Active Company_Name :
Hangzhou Jiuyuan Gene Engineering Co Ltd

Active Indication_Name:
Overweight

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:
Approved

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
CD44 Rabbit mAb Epigenetics
CEACAM6 Antibody (YA3351) supplier
SPHK1 Antibody: SPHK1 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 42 kDa, targeting to SPHK1. It can be used for WB,IHC-P,FC assays with tag free, in the background of Human.

Author: Interleukin Related

Related Posts